Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.

ABSTRACT:

Background

Brentuximab vedotin (BV) is an antibody-drug conjucate (ADC) comprising a CD30-directed antibody, conjugated to the microtubule-disrupting agent MMAE via a protease cleavable linker. BV is FDA approved for use in relapsed classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). There are multiple publications for its utility in other malignancies such as diffuse large B-cell lymphoma (DLBCL), mycosis fungoides (MF), Sézary syndrome (SS), T-cell lymphomas (TCL), primary mediastinal lymphoma (PMBL), and post-transplant lymphoproliferative disorders (PTLD). We believe that BV could potentially provide a strong additional treatment option for patients suffering from NHL.

Objective

Perform a systematic review on the use of BV in non

SUBMITTER: Berger GK 

PROVIDER: S-EPMC5218629 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature